The Chinese pharma industry experienced a 51% rise in new job postings in Q2 2023 compared with the previous quarter, with the highest share accounted for by AstraZeneca with 929 job postings according to GlobalData’s analysis of pharma company job postings. GlobalData’s China Contract Manufacturing Market Outlook provides a comprehensive analysis of the Chinese pharmaceutical contract manufacturing industry, highlighting key trends, players, investment opportunities, and value chain insights. Buy the report here.
Notably, Healthcare Practitioners and Technical Occupations jobs accounted for a 15% share of the Chinese’s pharma industry new job postings in Q2 2023, up by 62% over the prior quarter.
Healthcare Practitioners and Technical Occupations drive pharma hiring activity
Of the industry's total hiring activity, the highest number of new job postings were for Healthcare Practitioners and Technical Occupations, which accounted for 15% of the total new job postings in Q2 2023 and were down by 25% year-on-year. Second highest were Management Occupations, which accounted for 14% and drop by 32% year-on-year, and third highest were Sales and Related Occupations, which were 158% of the new job postings and 76% higher year-on-year.
Top five companies in pharma accounted for 57% of hiring activity
The highest number of jobs were posted by AstraZeneca with 929, followed by Pfizer with 644, while the highest increase was at Merck at 11%.
For further understanding of GlobalData's China Contract Manufacturing Market Outlook – Trends, Ambitions, Key Players, Investment and Value Chain, buy the report here.